




Precision Sensorimotor Control in Aging Fragile X Mental 
Retardation 1 Gene Premutation Carriers 
By 
  © 2019 
Walker S. McKinney 
B.S, Northwestern University, 2017 
Submitted to the graduate degree program in Clinical Child Psychology and the Graduate 
Faculty of the University of Kansas in partial fulfillment of the requirements  





Chair: Matthew W. Mosconi, Ph.D. 
 
 
Steven F. Warren, Ph.D. 
 
 
Eric M. Vernberg, Ph.D., ABPP 







The thesis committee for Walker S. McKinney certifies that this is 
the approved version of the following thesis: 
Precision Sensorimotor Control in Aging Fragile X Mental 












Date Approved: 1 July 2019 
iii 
Abstract 
Individuals with premutation alleles of the FMR1 gene are at risk of developing Fragile 
X-associated Tremor/Ataxia Syndrome (FXTAS), a neurodegenerative condition affecting 
sensorimotor, cognitive and psychological function. There is limited information on quantitative 
symptom traits in aging premutation carriers to assist in identifying neurodegenerative processes 
and understanding neurodegenerative mechanisms. 26 FMR1 premutation carriers ages 44-77 
years and 31 age-matched healthy controls completed a visually guided precision gripping task 
in which they pressed with their thumb and forefinger against load cells while receiving visual 
feedback. Individuals maintained a constant force for 2- or 8- seconds. During initial pressing, 
reaction time, the rate at which individuals increased their force, and force accuracy were 
measured. During sustained gripping, the complexity of the force time series, force variability, 
and mean force were examined. At the end of each trial, the rate at which individuals decreased 
their force was measured. During initial pressing, premutation carriers, relative to controls, 
showed longer reaction times, particularly at younger ages. They also showed reduced rates of 
force generation and reduced accuracy relative to controls. During sustained force, premutation 
carriers demonstrated reduced force complexity, though this effect varied as a function of age 
and hand; it was reduced across ages for the non-dominant hand but was more severely reduced 
at younger ages for the dominant hand. Lower sustained force complexity was associated with 
greater cytosine-guanine-guanine (CGG) repeat length. Increased reaction time, increased 
sustained force variability, and increased rates of force relaxation each were associated with 
more severe clinically rated FXTAS symptoms. Findings of increased reaction time in 
premutation carriers implicate neurodegenerative processes affecting the ability to rapidly 
prepare the motor system for action. Premutation carriers also showed reduced accuracy of their 
iv 
initial force output indicating impairments precisely planning rapid motor behavior. Reduced 
complexity of sustained motor output suggests deficits in reactively adjusting motor behavior in 
response to sensory feedback. Overall, these results indicate that sensorimotor issues in aging 
premutation carriers affect multiple motor systems, and quantitative tests of precision visuomotor 
ability may serve as key targets for monitoring FXTAS risk and progression. 
Keywords: Fragile X-associated tremor/ataxia syndrome, FMR1 premutation, 
sensorimotor, precision grip, neurodegeneration, bradykinesia, dysmetria 
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Precision Sensorimotor Control in Aging Fragile X Mental Retardation 1 Gene Premutation 
Carriers 
Fragile X is the most common heritable form of intellectual disability, and it is caused by 
“full” mutations of the FMR1 gene consisting of >200 cytosine-guanine-guanine (CGG) repeats 
(Kremer et al., 1991; Verkerk et al., 1991; Yu et al., 1991). Premutations of the FMR1 gene 
involving 55-200 CGG repeats also confer risk for multiple subclinical issues as well as medical, 
psychiatric, and neurodegenerative conditions (Lozano, Rosero, & Hagerman, 2014) including 
fragile-X associated tremor/ataxia syndrome (FXTAS). FXTAS is a neurodegenerative disease in 
which patients present with a variety of motor, cognitive, psychiatric and medical issues, as well 
as cerebellar and cortical degeneration typically beginning at ages 50-70 years (Brunberg et al., 
2002; Jacquemont et al., 2003). The defining clinical symptoms of FXTAS include intention 
tremor, gait ataxia, and Parkinsonism (Hagerman et al., 2001; Jacquemont et al., 2003; Juncos et 
al., 2011; Leehey et al., 2007), though some patients demonstrate severe decline in cognitive 
processes or the development of psychiatric issues (Grigsby et al., 2008). Pathology of the 
middle cerebellar peduncle (MCP sign), cerebral atrophy, and intranuclear inclusions also are 
associated with FXTAS (Brunberg et al., 2002; Greco et al., 2006). Still, symptom presentation 
is highly variable across patients, and objective, quantitative tools are needed to identify aging 
premutation carriers most at risk of developing FXTAS, track disease progression, and determine 
central mechanisms (Jacquemont et al., 2004; Leehey et al., 2007). 
Prior quantitative studies have indicated that premutation carriers with FXTAS and 
elderly, asymptomatic premutation carriers each show sensorimotor issues. For example, FXTAS 
patients show increased postural sway relative to healthy aging individuals (Aguilar et al., 2008), 
while aging premutation carriers with and without FXTAS each have shown greater postural 
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sway during standing associated with greater CGG repeat length (Kraan et al., 2013; O'Keefe et 
al., 2015; Wang, Khemani, Schmitt, Lui, & Mosconi, 2019). Studies of fine motor abilities 
critical to everyday activities have indicated that asymptomatic FMR1 premutation carriers 
(Shickman et al., 2018) and FXTAS patients (Schneider et al., 2012) show reduced motor 
planning speed. Park and colleagues also reported increased force variability during sustained 
finger abductions suggesting alterations in the ability to reactively adjust precision motor 
behavior in response to sensory feedback (Park et al., 2019). Importantly, Shickman and 
colleagues documented that more severe fine motor issues were associated with greater CGG 
repeat length in asymptomatic aging premutation carries, suggesting fine motor deficits may 
covary with FXTAS risk (Shickman et al., 2018). While these studies indicate tests of fine motor 
control may be useful for quantifying clinical and subclinical issues in aging premutation 
carriers, precise and translational measurements of multiple fine motor processes, including the 
initiation, maintenance, and termination of behavior, are needed to define affected systems, 
clarify neurobiological mechanisms of FXTAS, and monitor both disease risk and progression. 
One candidate approach for characterizing the multiple fine motor processes associated 
with FXTAS is studying visually guided precision gripping. Precision gripping is important for 
many daily living activities (e.g., writing, grasping objects), and multiple studies have 
documented atypical precision gripping behavior in neurodevelopmental (Mosconi et al., 2015; 
Wang et al., 2015) and neurodegenerative conditions that affects patients’ quality of life 
(Vaillancourt, Slifkin, & Newell, 2001a). Further, the neural bases of visually guided precision 
gripping have been studied extensively suggesting that clarifying spared and affected processes 
may help identify brain mechanisms in patient populations (Ehrsson et al., 2000; Kuhtz-
Buschbeck et al., 2008; Neely, Coombes, Planetta, & Vaillancourt, 2013; Prodoehl, Corcos, & 
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Vaillancourt, 2009). During precision gripping, individuals initiate a “rise phase” in which they 
rapidly increase their force output to reach a target level. Initial pressing is characterized by a 
transient force overshoot reflecting afferent delay of sensory feedback information (Desmurget et 
al., 1999; Potter, Kent, Lindstrom, & Lazarus, 2006). During a subsequent “sustained phase”, 
individuals aim to maintain a relatively constant level of force integrating feedforward and 
sensory feedback processes. Greater variability in force and reduced complexity of the force time 
series are seen in multiple patient populations and implicate failures in the ability to dynamically 
and reactively adjust precision motor output in response to sensory feedback (Chu & Sanger, 
2009; Vaillancourt, Slifkin, & Newell, 2001b). At the end of precision gripping actions, 
participants engage in a “relaxation phase” in which they rapidly release their grip force.  
In the present study, we characterized visually guided precision gripping behavior across 
rise, sustained and relaxation phases in FMR1 premutation carriers ages 44-77 years. Our 
primary goal was to characterize precision visuomotor behaviors in aging FMR1 premutation 
carriers. By examining a large age range, we were able to determine whether visually guided 
precision gripping issues were more prominent at relatively earlier stages of aging suggesting 
that they may be prodromal markers of degeneration, or whether they may become more 
prominent later suggesting decline at advanced ages. Gripping was tested across both hands to 
determine if neurodegenerative processes associated with aging in premutation carriers may be 
lateralized as previously suggested (Przybyla, Haaland, Bagesteiro, & Sainburg, 2011; Raw, 
Wilkie, Culmer, & Mon-Williams, 2012). We also examined the relationship between 
visuomotor outcomes, FXTAS clinical symptoms, and CGG repeat length to determine the utility 
of our measures for objectively characterizing neuromotor degeneration associated with the 




Twenty-six premutation carriers and 31 controls completed visuomotor testing (Table 1). 
No premutation carriers had an existing diagnosis of any neurological disorder, nor did they self-
report any motor (e.g., gait ataxia, intention tremor) or memory issues. Controls were excluded 
for current or past neurodegenerative, neurological, or major psychiatric disorders (e.g., 
schizophrenia, bipolar disorder). Controls also were excluded for a family history of fragile X 
syndrome or intellectual/developmental disabilities in first- or second-degree relatives. 
Participants were excluded if they reported any neurological or musculoskeletal disorder that 
could potentially cause atypical motor functioning or a history of medications known to affect 
motor functioning, including antipsychotics, stimulants, or benzodiazepines (Reilly, Lencer, 
Bishop, Keedy, & Sweeney, 2008). 
FMR1 premutation carriers were identified through local fragile X clinics and postings on 
local and national fragile X association listservs. Control participants were recruited through 
community advertisements. This study was carried out in accordance with the recommendations 
of and was approved by the University of Texas, Southwestern Institutional Review Board. All 
subjects provided written informed consent after a complete description of the study in 
accordance with the Declaration of Helsinki. 
Neurological and Radiological Evaluations 
FMR1 premutation carriers completed a clinical exam by a neurologist with expertise in 
movement control in aging (Pravin Khemani). The clinical exam included administration of the 
International Cooperative Ataxia Rating Scale (Trouillas et al., 1997). The ICARS is comprised 
of 19 sections examining postural and gait disturbances, ataxia, dysarthria and oculomotor 
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behavior. Higher scores indicate more severe neuromotor issues. The ICARS has been validated 
previously for diagnosis of ataxia in patients with focal cerebellar lesions (Schoch et al., 2007), 
hereditary spinocerebellar and Friedrich’s ataxia (Schmitz-Hubsch et al., 2006). 
Sixteen FMR1 premutation carriers also underwent a T2-weighted MRI scan (repetition 
time = 6350 msec; echo time = 100 msec; flip angle = 120º; field of view = 256 × 156 × 
256mm3; 78 axial slices; 1 × 1 × 2mm3 voxels; no gap) to test for presence of the MCP sign, 
cerebral atrophy or hyperintensities, or other cerebral, brainstem, or cerebellar alterations 
consistent with a diagnosis of FXTAS (Jacquemont et al., 2003).  
Visuomotor Testing 
Participants completed two tests of visuomotor behavior differentiated by the trial 
duration (“pulse” trials were 2-sec and “sustained” trials were 8-sec). For both tests, stimuli were 
presented on a 102 cm (40 inches) Samsung LCD monitor with a resolution of 1366 ×768 and a 
120 Hz refresh rate. Participants were tested in a darkened room while seated 52 cm from the 
display monitor with their elbow at 90° and their forearm resting in a relaxed position on a 
custom-made arm brace. The arm brace was clamped to a table to keep the participant's arm 
position stable throughout testing (Figure 1). The participant's hand was pronated and lay flat 
with digits comfortably extended. Participants used their thumb and index finger to press against 
two opposing precision load cells (ELFF-B4-100N; Entran) 1.27 cm in diameter secured to a 
custom grip device attached to the arm brace. A Coulbourn (V72-25) resistive bridge strain 
amplifier received analog signal from the load cells. Data were sampled at 200 Hz with a 16-bit 
analog-to-digital converter (DI-720; Dataq Instruments). Data were converted to Newtons of 




Before testing, each participant's maximum voluntary contraction (MVC) was calculated 
separately for each hand using the average of the maximum force output during three trials in 
which participants pressed as hard as they could for three seconds.  
 During visuomotor testing, participants viewed a horizontal white force bar that moved 
upward with increased force and downward with decreased force and a static target bar that was 
red during rest and turned green to cue the participant to begin pressing at the beginning of each 
trial (Figure 2). Participants received two instructions: (1) press the load cells as quickly as 
possible when the red target bar turns green, and (2) keep pressing so that the force bar stays as 
steady as possible at the level of the green target bar. These instructions were identical for the 
two versions of the task described below. 
 “Pulse” (2-second) and “sustained” (8-second) trials were administered at 15%, 45%, 
and 85% of each individual’s MVC. During the pulse test, two blocks of five trials were 
presented for each hand at each force level (2 hands x 3 force levels x 2 blocks x 5 trials = 60 
pulse trials). Each 2-s pulse trial alternated with 2-s rest periods. A 15-s rest block was provided 
after each block of trials. During the sustained test, participants completed two blocks of three 
trials for each hand at each force level (2 hands x 3 force levels x 2 blocks x 3 trials = 36 
sustained trials). Eight-second trials were followed by 8-s rest periods, and each block was 
separated by 15-s of rest. For both tests, the same hand was never tested on consecutive blocks. 
The order of force levels was randomized across blocks. The order of the two experiments was 
randomly assigned to each participant. Participants self-reported their handedness. 
Visuomotor Data Processing 
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Force traces for each trial were low-pass filtered via a double-pass 4th-order Butterworth filter at 
a cutoff of 15 Hz in MATLAB. Data were analyzed using custom MATLAB scripts previously 
developed by our lab (Wang et al., 2015). 
Data from three distinct phases were analyzed. During the initial rise phase in which 
individuals pressed on the load cells to reach the target level, force level is guided primarily by 
feedforward processes completed prior to the availability of visual and other sensory feedback 
processes to guide force output (Ghez, Hening, & Gordon, 1991; Prablanc & Martin, 1992). We 
examined the latency to rise onset, peak rate of force increase (i.e., the maximum value of the 
first derivative of the force trace), duration of the rise phase, and accuracy of the rise phase. The 
onset of the rise phase was calculated as the time at which the rate of force increase first 
exceeded 5% of the peak rate of force increase and remained above this level for at least 100ms 
(Grafton & Tunik, 2011; Wang et al., 2015). Reaction time was calculated as the difference 
between rise phase onset and the appearance of the start cue. The rise phase offset was calculated 
as the time-point when the rate of force increase fell below 5% of the peak rate of force increase, 
and the force level was within 90% to 110% of the mean force of the sustained phase (Wang et 
al., 2015). The peak rate of force increase was defined as the maximum value of the first 
derivative of the force trace. Rise phase duration was then calculated as the difference between 
the rise phase offset and rise phase onset. Due to the known effect of participant MVC on peak 
rate of force increase and rise phase duration (i.e., rate of force generation and duration both 
increase asymptotically with increases in force output), rate of force increase and duration of 
initial force output were analyzed relative to MVC (i.e., rate of force increase/MVC; rise phase 
duration/MVC). Finally, force accuracy for the rise phase was calculated as the force at rise 
offset divided by the target force (i.e., 𝑅𝑖𝑠𝑒 𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 =  
(𝐹𝑟𝑖𝑠𝑒)
(𝐹𝑡𝑎𝑟𝑔𝑒𝑡)
 ). Values below 1 represent an 
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undershooting of the target force and values above 1 reflect overshooting of the target force. An 
accuracy score of 1 would indicate perfect accuracy. The entire rise phase was excluded if 
participants began gripping before the start cue, or if they returned to baseline prior to reaching 
90% of the target force. Rise phase data for both the pulse and sustained tasks were analyzed 
within the same model to allow for the analysis of a task effect (i.e., pulse vs. sustained).  
To determine the extent to which participants could maintain a constant level of force, the 
sustained phase was examined and defined as the period following rise phase offset and prior to 
the appearance of the stop cue. Due to the brief duration of pulse trials in which force levels are 
highly variable, only 8-s trials were used to examine the sustained phase. The mean force of the 
time series was calculated to determine individuals’ ability to complete the task. The variability 
of the force time series was calculated using the following procedures: first, force data were 
linearly detrended to account for systematic changes in mean force over the course of the trial 
(e.g., data drift). Second, the within-trial standard deviation (SD) of the force time series was 
calculated. To examine the time-dependent structure of the time series, the approximate entropy 
(ApEn) was calculated for each trial (Mosconi et al., 2015; Pincus & Goldberger, 1994; Slifkin 
& Newell, 1999; Vaillancourt et al., 2001b). ApEn returns a value between 0 and 2, reflecting 
the predictability of future values in a time series based on previous values. For example, a sine 
wave has accurate short- and long-term predictability, corresponding to an ApEn value near 0. 
High irregularity of the data, reflective of the independence of each force value, returns an ApEn 
near 2. The algorithm and parameter settings for these calculations (m = 2; r = 0.2 × standard 
deviation of the signal) were identical to previous work (Vaillancourt & Newell, 2000). 
Sustained phase variables were excluded if fewer than 4 seconds of data were available or if 
participants returned to baseline for more than 1 second (e.g., a > 1 sec dip of the force signal).  
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In order to determine the rate at which individuals released force at the end of trials, the 
relaxation phase also was examined. The onset of the relaxation phase was defined as the first 
point following the stop cue (target bar turned red) at which velocity (i.e., rate of change of 
force) went below 5% of the peak velocity and remained at that level or below for at least 
100ms. The offset of the relaxation phase was defined as the first point at which velocity rose 
back above 5% of the peak relaxation velocity. We examined the rate of force decrease during 
the relaxation phase. The peak rate of force decrease was identified as the minimum value of the 
first derivative of the force trace following the stop cue. Again, due to the potential impact of 
participant MVC on peak rate of force decrease, this measurement was then divided by MVC. 
Thus, relaxation data is relative to each participant’s individual strength. Relaxation phases were 
not included if the participant released force prior to the stop cue. Relaxation phase data for both 
the pulse and sustained tasks were analyzed within the same model to allow for the analysis of a 
task effect (i.e., pulse vs. sustained). 
CGG Repeat Count 
All premutation carriers provided blood samples to confirm premutation status. FMR1 
CGG repeat count was quantified using molecular testing conducted at Dr. Elizabeth Berry-
Kravis’ Molecular Diagnostic Laboratory at Rush University. Genomic DNA was isolated from 
peripheral blood leukocytes samples. The FMR1 polymerase chain reaction (PCR) test with 
quantification of allele-specific CGG repeat count was performed using commercially available 
kits (Asuragen, Inc., Austin, TX). For women, CGG repeat analyses reflect the longest CGG 
repeat of the two alleles. 
Cognitive Measures 
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Cognitive functioning was assessed using the abbreviated battery of the Stanford-Binet 
Intelligence Scales, Fifth Edition (SB-5) including nonverbal fluid reasoning and verbal 
knowledge sub-sections (Roid, 2003). One participant did not complete the SB-5 due to not 
being fluent in English. 
Statistical Analyses 
To determine whether visuomotor ability differed according to premutation carrier status 
and to determine if the relationship between age and visuomotor outcomes varied as a function 
of group, general linear multilevel mixed effect (MLM) analyses were conducted. This approach 
allows for the simultaneous examination of within- and between-subject fixed effects while 
allowing within-subject factors to differ for each participant as random effects. Additionally,  
these analyses allowed for the analysis of interactions within the repeated measures design 
without listwise deletion of participant data (e.g., if a participant had a shortened testing session 
and only completed the task with one hand). Task/condition effects (percent MVC, hand, task) 
were identified as level 1 predictors and subject effects (group, age) were identified as level 2 
predictors. Random variance components for the intercept (subject) and the slope of target force 
level (percent MVC) also were analyzed. To maintain relatively parsimonious models, the four- 
and five-way interaction between factors were not analyzed. Initial models included all two- and 
three-way interactions, after which variables and interactions were removed and model fit was 
compared between the previous and current models using a likelihood ratio test. Only variables 
which significantly (p < .05) improved model fit were incorporated into the final models. All 
model predictors were centered. Mixed effect modeling was conducted using the lmer package 
within R version 3.4.4. 
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Due to the non-normal distribution of CGG repeat length and ICARS scores, the 
relationships between visuomotor outcomes, ICARS scores, and CGG repeat length were 
examined using Spearman’s rank-order correlations. Linear regression was used to determine if 
total ICARS scores were related to age, CGG repeat length, or the interaction of age and CGG 
repeat length. Due to the large number of correlations that were performed, only results with p < 
.01 were interpreted as significant. Correlational and regression analyses were conducted using 
IBM SPSS Statistics 25. 
Results 
Demographics  
Healthy controls had significantly higher full-scale IQs (M = 109.3, SD = 12.8) than 
premutation carriers (M = 99.5, SD = 12.1), t(54) = 2.93, p < .01, though IQ was in the average 
range for both groups (Table 1). Controls and carriers did not differ on age, sex ratio, or 
handedness. Nine premutation carriers did not complete the clinical evaluation due to scheduling 
difficulties. For the 17 premutation carriers who completed the clinical visit, ICARS scores are 
presented in Table 1. Increased age was significantly associated with increased ICARS scores 
(F(1,15) = 9.858, p = .007, R2 = .397). The addition of CGG repeat length to this model did not 
significantly improve fit (FΔ(1,14) = 1.891, p = .191, R2Δ = .072), nor did the interaction 
between age and CGG repeat length (FΔ(1,13) = .515, p = .486, R2Δ = .020). 
MVC 
Premutation carriers and controls did not differ on MVC (β = -6.222, SE = 7.368, p = 
.402). No lateralized differences in MVC between groups were seen (group x hand: β = 7.303, 
SE = 3.971, p = .072). 
Rise Phase 
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Fixed effect estimates and random effect variances as well as their associated standard 
error values for rise phase models are presented in Tables 2 (reaction time and initial rate of 
force increase) and 3 (duration and accuracy). 
Participants showed shorter reaction times during the pulse task relative to the sustained 
task (β = 0.086, SE = 0.012, p < .001). Additionally, reaction time increased with increases in 
target MVC percent (β = 0.072, SE = 0.014, p < .001) and age (β = 0.049, SE = .023, p = .034). 
FMR1 premutation carriers demonstrated longer reaction times than controls, especially at 
younger ages and during the pulse compared to the sustained task (Figure 3; group x task x age: 
β = -0.099, SE = 0.028, p < .001).  
Participants demonstrated a higher rate of force increase during the pulse compared to the 
sustained task (β = -0.386, SE = 0.046, p < .001). Rate of force increase was greater at higher 
compared to lower MVC target levels (β = 1.987, SE = 0.082, p < .001). Multiple three-way 
interactions were significant. For each of these interactions, premutation carriers showed a 
reduced rate of force increase relative to controls, but this was most severe at higher force levels 
of the pulse compared to the sustained task (Figure 4; group x task x percent MVC: β = 0.625, 
SE = 0.217, p = .004), at younger ages and during the pulse compared to the sustained task 
(group x task x age: β = -0.316, SE = 0.104, p = .002), and at younger ages and at higher percent 
MVC levels (group x percent MVC x age: β = 0.339, SE = 0.169, p = .049). 
For all participants, rise phase duration was greater during the pulse task compared to the 
sustained task (β = -0.004, SE = 0.0003, p < .001) and scaled with target MVC level (β = 0.001, 
SE = 0.0004, p = .003). Relative to controls, premutation carriers showed longer rise phase 
duration than controls, but only for their dominant hand (group x hand: β = -0.002, SE = 0.0006, 
p = .002).  
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 Participants overshot target force levels more during the rise phase of the pulse compared 
to the sustained task (β = -0.015, SE = 0.004, p < .001). Specifically, participants initially 
overshot target force levels during the 15% MVC condition but not the 45% or 85% MVC 
conditions (β = -0.075, SE = 0.008, p < .001). Premutation carriers showed increased target 
overshoot relative to controls that was more severe when they used their non-dominant hand 
during the pulse task (group x hand x task: β = -0.033, SE = 0.016, p = .044) and when using the 
non-dominant hand at lower force levels (Figure 5; group x hand x percent MVC: β = -0.047, SE 
= 0.020, p = .017).  
Sustained Phase 
The fixed effect estimates and random effect variances as well as their associated 
standard errors for all sustained phase models are presented in Table 4. 
Participants demonstrated reduced ApEn at higher compared to lower target force levels 
(β = -0.124, SE  = 0.014, p < .001). Premutation carriers showed reduced ApEn relative to 
controls, but this group difference varied as a function of age and hand tested (Figure 6; group x 
hand x age: β = -0.041, SE  = 0.017, p = .014). Specifically, premutation carriers showed 
reduced ApEn across age for the non-dominant hand, but this effect was more severe at younger 
ages relative to older ages for the dominant hand. 
 Force SD scaled with target MVC level (β = 3.348, SE = 0.477, p < .001), and force SD 
was greater for the non-dominant relative to dominant hand for participants (β = 0.470, SE = 
0.180, p = .010). There were no group differences or group interactions for force SD. 
Mean sustained force scaled with target MVC level (β = 54.478, SE = 2.371, p < .001). 
Compared to controls, premutation carriers demonstrated lower mean force with their dominant 
hand only (group x hand: β = 3.480, SE = 0.988, p < .001). 
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Relaxation Phase 
At the end of trials, participants decreased their force level more rapidly during higher 
relative to lower target force levels (β = 4.188, SE = 0.098, p < .001) and during the pulse 
compared to the sustained force trials (β = -0.203, SE = 0.033, p < .001). There were no 
significant group differences or group interactions for rate of force decrease.  
Visuomotor Behavior and Clinical/Demographic Outcomes 
CGG repeat length. The relationships between CGG repeat length and visuomotor 
behavior are presented in Table 5. Greater CGG repeat length was associated with reduced non-
dominant hand ApEn in the 45% MVC condition (Figure 7A; ρ = -.529, p = .009). No other 
visuomotor variables were associated with CGG repeat length. 
 Clinical symptoms. The relationships between total ICARS scores and visuomotor 
behavior are presented in Table 6. More severe total ICARS scores were associated with greater 
reaction times during the pulse task in the dominant hand 15% MVC condition (ρ = .774, p = 
.003), dominant hand 85% MVC condition (ρ = .724, p = .008), and non-dominant hand 85% 
MVC condition (Figure 7B; ρ = .795, p = .002). More severe total ICARS scores also were 
associated with greater reaction times during the dominant hand 15% MVC condition of the 
sustained task (ρ = .612, p = .009). More severe ICARS scores were associated with higher force 
SD during the non-dominant hand 45% MVC condition (Figure 7C; ρ = .663, p = .004). 
Additionally, more severe total ICARS scores were associated with more negative (i.e., quicker) 
rates of force decrease during the relaxation phase of the pulse task dominant hand 15% MVC 
(Figure 7D; ρ = -.827, p < .001) and 45% MVC conditions (ρ = -.841, p < .001).  
Discussion 
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Despite sensorimotor impairments being central to the diagnosis of FXTAS, few studies 
have quantified precision sensorimotor behaviors in aging FMR1 premutation carriers. Here, we 
examined multiple components of precision visuomotor behavior in aging premutation carriers, 
including initial force output, sustained precision motor behavior, and the rate of force 
termination. Five key findings are documented. First, younger premutation carriers demonstrated 
longer reaction times than controls indicating delays in generating visually cued motor behavior 
may be present during early stages of aging. Second, aging premutation carriers demonstrated a 
reduced ability to rapidly increase force during precision gripping, suggesting that initial motor 
output is slowed. Third, premutation carriers showed a larger overshoot of target force levels 
during initial force generation implicating reduced accuracy of internal action plans. Fourth, 
younger premutation carriers demonstrated reduced complexity of their sustained force output 
(i.e., ApEn), suggesting the ability to dynamically adjust motor output in response to sensory 
feedback may be impacted, especially during initial stages of aging during which premutation 
carriers first become vulnerable to FXTAS-associated deterioration. Last, multiple impairments 
of rise, sustained, and relaxation phases of visuomotor behavior were associated with clinically 
rated neuromotor issues in premutation carriers, indicating that select precision measures of 
visuomotor behavior may covary with FXTAS risk or progression. 
Reaction Time Slowing in Aging FMR1 Premutation Carriers 
 We observed increased reaction time in premutation carriers relative to healthy controls, 
and this effect was more severe at younger ages during rapid motor action (pulse task). Delayed 
reaction times in premutation carriers could reflect slowing of initial visual processing, delays in 
“premotor time” during which individuals translate sensory cues into a motor command, or 
slowing of the motor command and execution (Stelmach & Worringham, 1988). Based on the 
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specificity of premutation carriers’ reaction time delays to the pulse task in which they had less 
preparatory time than sustained test conditions (2 vs. 8 sec), our findings implicate delays in 
premotor time or slowing of the motor command and execution. During a rapid motor task, 
relative to the sustained task, individuals have little time after a trial to prepare for the onset of 
the subsequent trial. During this premotor phase, individuals must prepare both an accurate and 
timely motor response, while flexibly shifting between gripping and relaxation. However, we 
observed increased reaction time independent of force level suggesting that delays in reaction 
time are not attributable to a slowed rate of actively engaging and increasing the firing rates of 
motor units but instead reflect delays in planning rapid actions. 
 Elevated reaction times in premutation carriers also were specific to younger premutation 
carriers among our aging adult sample, suggesting premutation carriers show degeneration of 
premotor response processes earlier than controls, but that overall levels of deterioration are 
similar by ages 60-70 years. It is important to note that none of the premutation carriers studied 
here self-reported clinical concerns of FXTAS, and our clinical data confirmed that premutation 
carriers in this study demonstrated reduced symptoms relative to FXTAS samples previously 
characterized using the ICARS (Berry-Kravis et al., 2003; Loesch, Churchyard, Brotchie, Marot, 
& Tassone, 2005). In the context of prior results indicating that the mean age of onset of FXTAS 
is 61 years (Tassone et al., 2007), our finding that delayed reaction times in premutation carriers 
are specific to ages 44-60 years suggests that alterations of motor planning processes may be 
specific to aging individuals who are still more susceptible to FXTAS. In contrast, elderly 
premutation carriers who have not experienced significant clinical deterioration prior to this age 
may show normative rates of reaction time slowing as they advance in age. Longitudinal studies 
will be needed to determine the extent to which slowed reactions times during rapid motor 
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actions may serve as prodromal markers of FXTAS for premutation carriers across aging and 
into elderly years. 
Rapid Force Production in FMR1 Carriers 
Reduced rates of force increase and increased time to reach target force levels in aging 
premutation carriers together suggest impairment in the ability to rapidly increase force output 
during precision motor actions. These findings are not attributable to diminished overall force 
output as groups did not differ on MVC, and the overall amount of individuals’ force generation 
was controlled in our analyses. Instead, premutation carriers appear to have a reduced ability to 
rapidly generate force, suggesting that the bradykinesia associated with FXTAS (Niu et al., 
2014) may be evident in some asymptomatic premutation carriers. Similar reductions in initial 
force production also have been reported in studies of Parkinson’s disease suggesting basal 
ganglia circuit functions may be affected during aging in premutation carriers (Fellows, Noth, & 
Schwarz, 1998; Stelmach & Worringham, 1988). This hypothesis is supported by studies 
highlighting increased iron deposition in neuronal and glial cells in putamen nuclei of FXTAS 
patients (Ariza et al., 2017) and case studies documenting pre- and postsynaptic nigrostriatal 
dysfunction (Healy et al., 2009; Scaglione et al., 2008; Zuhlke et al., 2004). Our findings also 
could reflect peripheral alterations. Although premutation carriers demonstrated similar MVCs 
compared to controls, atypical recruitment of motor neurons during voluntary muscle 
contractions is possible (Park et al., 2019; Rose & McGill, 2005; Wang et al., 2017). For 
example, a previous study has documented slower nerve conduction velocities and F-wave 
latencies in male premutation carriers with and without FXTAS (Soontarapornchai et al., 2008). 
EMG abnormalities, including reduced motor unit firing rates, have been reported in premutation 
carriers and FXTAS patients, indicating that difficulties generating force stem from alterations at 
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the neuromuscular level (Bravo et al., 2018; Lechpammer et al., 2017; Park et al., 2019). Both 
functional neuroimaging and EMG studies are needed to clarify mechanisms contributing to 
atypical rapid force production in premutation carriers. 
At lower force levels (i.e., 15% and 45% MVC), premutation carriers showed a pattern of 
target overshooting compared to healthy controls. Movement dysmetria has been reported in 
several FXTAS case studies (Hagerman et al., 2004; Hall, Fraint, & Dafer, 2018), and our results 
add to these data suggesting that difficulties in feedforward motor planning also are present in 
asymptomatic aging premutation carriers. Whereas premutation carriers showed relatively intact 
abilities to produce accurate initial motor output at high force levels, their selective difficulties in 
overshooting low target force levels suggests reduced precision during more challenging fine 
motor tasks. Transient overshooting reflects imprecision in initial motor plans that is rapidly 
corrected in response to sensory feedback as seen at higher force levels that take longer to reach. 
This disproportionate impairment in the ability to plan fine motor behavior may have significant 
clinical consequences during activities of daily living, such as handwriting, as reported in prior 
case studies (Hagerman et al., 2012). Our finding that greater overshooting in premutation 
carriers was more prominent in the non-dominant relative to dominant hand suggests that 
feedforward motor deficits may have less impact initially during more skilled actions (e.g., those 
completed by the dominant hand). Given that our groups were matched on handedness, however, 
it is not likely that neurodegenerative processes affecting aging FMR1 premutation carriers 
selectively compromise the right or left hemisphere. 
Sustained Visuomotor Control in FMR1 Premutation Carriers 
During sustained force contractions, FMR1 premutation carriers showed lower time 
series complexity (reduced ApEn) reflecting a reduced ability to dynamically adjust force output 
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in response to sensory feedback. Increased complexity of force output is adaptive and reflects 
individuals’ ability to integrate multiple sensory feedback and feedforward processes and update 
their internal action model. Reduced complexity suggests reduced integration of these distinct 
processes and reduced ability to optimize precise sensorimotor behavior. Our finding that the 
severity of reduced sensory feedback control of force behavior in premutation carriers is 
relatively similar in magnitude across ages for the non-dominant hand, but more prominent at 
younger ages for the dominant hand indicates that deterioration of sustained sensorimotor motor 
behavior may be lateralized in aging premutation carriers. More specifically, our results suggest 
that healthy controls show worsening of their sustained force control as they age, whereas the 
opposite pattern is true for premutation carriers when using the dominant hand. We postulate that 
older premutation carriers in our sample who currently report being asymptomatic may be less 
affected by the premutation, and less likely to develop FXTAS than the younger individuals in 
our sample who are beginning to age into the period of adulthood during which they are most 
likely to develop FXTAS symptoms. This hypothesis is supported by evidence that FXTAS 
prevalence decreases during late adulthood reflecting increased FXTAS-related mortality rates 
and reduced likelihood of FXTAS onset during elderly years (Rodriguez-Revenga et al., 2009). 
Greater complexity for dominant compared to non-dominant hand performance in younger 
healthy controls likely accounts for the lateralized pattern of deficit seen in premutation carriers 
who showed similar levels of force complexity across hands. 
Reduced complexity of the time-dependent structure of force oscillations in younger 
premutation carriers may reflect a reduced number of neural oscillators, as has been suggested by 
prior studies documenting reduced movement complexity in Parkinson’s disease (Vaillancourt et 
al., 2001b). Neural oscillators within the central nervous system each generate rhythmic output. 
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Corticomotor neurons demonstrate preferred discharge frequencies, and so the use of a larger 
number of neural oscillators to generate motor output would result in greater complexity of 
motor output as each neural oscillator contributes output of a different frequency (McAuley & 
Marsden, 2000). Likewise, fewer neural oscillators generating motor output would result in the 
reduced variability of motor output timing consistent with a less complex and more rhythmic 
force output (McAuley & Marsden, 2000; Vaillancourt et al., 2001b). Our findings of reduced 
ApEn in premutation carriers thus implicate atypical integration of neural oscillators that may 
contribute to increased rates of tremor in premutation carriers (Homberg, Hefter, Reiners, & 
Freund, 1987). ApEn measurements during sustained visuomotor behavior hold promise for 
determining mechanisms contributing to tremor in FXTAS, and as surrogate biomarkers useful 
for clinical trials targeting tremor in patients (Hagerman et al., 2012). 
In addition to reduced complexity of their sustained force output, premutation carriers 
also showed reduced sustained mean force output indicating motor dysmetria during feedback-
guided visuomotor behavior. Reduced mean force may reflect peripheral weakness of 
neuromuscular processes in premutation carriers, though similar MVCs among premutation 
carriers and controls suggest motor weakness is not likely responsible for differences in mean 
force. Instead, mean force reductions likely indicate failures in sensory feedback guided motor 
behavior precision, consistent with a recent study documenting greater sustained force variability 
during finger abduction (Park et al., 2019). While we did not find evidence for atypical 
variability in our premutation carrier sample, our correlational analyses indicated that force 
variability was associated with more severe FXTAS symptoms suggesting that sustained 
sensorimotor dysmetria may be present in aging premutation carriers who are showing or 
beginning to show disease-related clinical issues.  
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Visuomotor Behavior and FXTAS  
 In addition to identifying multiple visuomotor behavioral alterations in aging premutation 
carriers, we also document strong relationships between visuomotor behavior and clinical 
symptoms of FXTAS. We found that increased reaction time, increased force variability, and 
faster rates of force relaxation each were associated with more severe clinically rated neuromotor 
issues in carriers suggesting that quantifiable deficits in multiple precision visuomotor behaviors 
may be part of the aging process in FMR1 premutation carriers, or that these issues may reflect 
early indicators of atypical neurodegeneration associated with FXTAS. Our findings that delays 
in motor preparation processes are present primarily at earlier ages for our sample suggest that 
some premutation carriers may not show this deterioration. Instead, slower reaction times may 
reflect early indicators of FXTAS disease risk or progression. Alternatively, aging premutation 
carriers may show earlier decay of initial motor preparation and planning processes relative to 
healthy aging, but their rate of decay may slow and normalize with age. Our finding that greater 
force variability is associated with more severe FXTAS symptoms in premutation carriers 
indicates that a reduced ability to precisely and consistently maintain a steady motor output in 
response to sensory feedback information may track with developing symptoms in premutation 
carriers. Increased sustained force variability also is consistent with known neuropathological 
indicators of FXTAS. As individuals sustain a constant level of force using visual feedback, 
visual input typically is translated into motor corrections through parietal-ponto-cerebellar 
pathways. The MCP serves as the primary process relaying parietal-ponto visual feedback 
information to cerebellum, where motor corrections are translated. Degeneration of the MCP, 
reflected as hyperintensities on T2-weighted scans, is symptomatic of FXTAS and may 
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contribute to both greater sensorimotor variability and FXTAS clinical symptoms (Jacquemont et 
al., 2003).  
Based on prior studies showing that greater CGG repeat length among premutation 
carriers increases risk for FXTAS (Tassone et al., 2007), our finding that reduced ApEn was 
related to increased CGG repeat length in premutation carriers also suggests that sustained 
visuomotor behavioral issues may covary with disease risk. From a more mechanistic 
perspective, greater CGG repeat length in the premutation range contributes to increased mRNA 
transcript, sequestration of proteins, and intranuclear inclusions (Greco et al., 2006; Li & Jin, 
2012). These inclusions have been documented in pontine and cerebellar cells in the majority of 
cases studied to date (Ariza et al., 2016; Greco et al., 2006), suggesting that greater CGG repeat 
length compromises ponto-cerebellar functions. The atypical sensorimotor behaviors identified 
in this study are consistent with this model and may serve as objective biobehavioral targets 
useful for understanding pathophysiological processes associated with FXTAS and quantifying 
clinically relevant changes in aging premutation carriers. 
Limitations 
 Several limitations of the present study should be acknowledged. First, larger samples of 
FXTAS patients and asymptomatic premutation carriers are needed to examine variability in 
visuomotor behavior during aging and determine disease-specific markers. Longitudinal samples 
are needed to track disease onset and progression and clarify the extent to which objective 
measures of visuomotor precision may track with disease course. Second, it will be critical to 
include movement disorder comparison groups in future studies of aging premutation carriers to 
determine the specificity of these metrics to this population, though we propose that the next 
critical step is to determine the specificity of key visuomotor issues to symptomatic compared to 
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asymptomatic FMR1 premutation carriers so that disease presence can be reliably identified in 
aging individuals who test positive for premutation alleles. Third, our sample consisted primarily 
of females who are at reduced risk for FXTAS relative to males. Despite 75% of our sample 
being female, we established multiple visuomotor issues in aging premutation carriers and 
identified multiple participants, both male and female, showing FXTAS symptoms. Inclusion of 
females in FXTAS studies is warranted, though larger samples that allow for direct comparisons 
of sensorimotor behavior in aging males and females are needed. Fourth, while we report 
behavioral findings in relation to CGG repeat length, measures of mRNA, methylation ratios, 
and FMR protein are important for clarifying how aberrant neurobiological processes contribute 
to FXTAS risk or prodromal symptoms. 
Conclusions 
 Our results identify multiple precision visuomotor issues in aging FMR1 premutation 
carriers and indicate that select visuomotor alterations track with FXTAS symptom severity. 
Together, these findings suggest that subclinical deficits of precision visuomotor behavior may 
be detectable prior to the onset of FXTAS and serve as key targets for tracking disease risk and 








(n = 31) 
Premutation Carriers 
(n = 26) 
  
t p 
Age (years) 53.29 (9.79) 56.77 (8.87) -1.39 .169 
Sex (% male) 
†
 38.7% 23.1% 1.60
†
 .206 
Handedness (% right) 
†
 90.3% 96.2% .737
†
 .391 
FSIQ 109.32 (12.83) 99.48 (12.07) 2.93 .005** 
ICARS total score - 5.47 (4.76) - - 
ICARS total range - 0-19 - - 
CGG repeat length - 82 (17) - - 
Note: FSIQ: full-scale IQ; ICARS: International Cooperative Ataxia Rating Scale; CGG: cytosine-









Fixed Effect Estimates  p Random Effect Variances  
Level 1 Variables   Level 1 residual (εit) 0.020 (0.142) 
Intercept 0.456 (0.022) < .001 Level 2 intercept (µ0i) 0.025 (0.158) 
% MVC 0.072 (0.014) < .001   
Task 0.086 (0.012) < .001   
Level 2 Variables     
Group 0.026 (0.045) .557   
Age 0.049 (0.023) .034   
Interaction Variables     
Group x Age -0.012 (0.045) .799   
Group x Task -0.014 (0.024) .575   
Task x Age -0.023 (0.014) .102   
Group x Age x Task -0.099 (0.028) < .001   
Rate of force 
increase 
Fixed Effect Estimates  p Random Effect Variances  
Level 1 Variables   Level 1 residual (εit) 0.288 (0.537) 
Intercept 1.894 (0.060) < .001 Level 2 intercept (µ0i) 0.169 (0.411) 
% MVC 1.987 (0.082) < .001 % MVC 0.205 (0.453) 
Hand 0.201 (0.044) < .001   
Task -0.386 (0.046) < .001   
Level 2 Variables     
Group -0.158 (0.120) .196   
Age -0.051 (0.062) .409   
Interaction Variables     
Group x % MVC -0.221 (0.164) .182   
Group x Age 0.335 (0.124) .009   
Group x Task 0.268 (0.091) .004   
% MVC x Age -0.032 (0.085) .707   
% MVC x Task -0.616 (0.109) < .001   
Task x Age -0.112 (0.052) .031   
Group x % MVC x Age 0.339 (0.169) .049   
Group x % MVC x Task 0.625 (0.217) .004   
Group x Age x Task -0.316 (0.104) .002   
Note: MVC: maximum voluntary contraction; Fixed effect estimate values are given as Estimate (Standard 
Error) and random effect variances are given as Variance (Standard Deviation); rate of force increase 








Fixed Effect Estimates  p Random Effect Variances  
Level 1 Variables   Level 1 residual (εit) 0.00001 (0.004) 
Intercept 0.014 (0.001) < .001 Level 2 intercept (µ0i) 0.00002 (0.005) 
% MVC 0.001 (0.0004) .003   
Hand -0.0001 (0.0003) .697   
Task -0.004 (0.0003) < .001   
Level 2 Variables     
Group 0.0005 (0.001) .714   
Age -0.0003 (0.0007) .698   
Interaction Variables     
Group x Hand -0.002 (0.0006) .002   
Task x Age 0.0009 (0.0004) .015   
Rise phase 
accuracy 
Fixed Effect Estimates  p Random Effect Variances  
Level 1 Variables   Level 1 residual (εit) 0.002 (0.049) 
Intercept 0.998 (0.003) < .001 Level 2 intercept (µ0i) 0.0004 (0.020) 
% MVC -0.075 (0.008) < .001 % MVC 0.002 (0.049) 
Hand 0.005 (0.004) .217   
Task -0.015 (0.004) < .001   
Level 2 Variables     
Group 0.009 (0.007) .192   
Interaction Variables     
Hand x % MVC -0.009 (0.010) 0.386   
Group x % MVC -0.014 (0.016) 0.362   
Group x Hand 0.005 (0.008) 0.540   
Task x Hand -0.002 (0.008) 0.809   
Group x Task -0.006 (0.008) 0.477   
Group x % MVC x Hand -0.047 (0.020) 0.017   
Group x Task x Hand -0.033 (0.016) 0.044   
Note: MVC: maximum voluntary contraction; Fixed effect estimate values are given as Estimate 
(Standard Error) and random effect variances are given as Variance (Standard Deviation); rise phase 
duration controls for participant MVC  
27 
Table 4  
 
Best Fitting Multilevel Models for Sustained Phase Variables 
 
ApEn 
Fixed Effect Estimates  p Random Effect Variances  
Level 1 Variables   Level 1 residual (εit) 0.006 (0.074) 
Intercept 0.428 (0.009) < .001 Level 2 intercept (µ0i) 0.003 (0.059) 
% MVC -0.124 (0.014) < .001 % MVC 0.005 (0.077) 
Hand -0.013 (0.008) .108   
Level 2 Variables     
Group -0.029 (0.017) .094   
Age 0.011 (0.009) .227   
Interaction Variables     
Group x Hand x Age -0.041 (0.017)  .014   
Group x Age 0.020 (0.017) .251   
Group x Hand -0.013 (0.016) .431   
Hand x Age 0.006 (0.008) .450   
Force SD 
Fixed Effect Estimates  p Random Effect Variances  
Level 1 Variables   Level 1 residual (εit) 2.760 (1.661) 
Intercept 1.673 (0.189) < .001 Level 2 intercept (µ0i) 1.569 (1.253) 
% MVC 3.348 (0.477) < .001 % MVC 10.207 (3.195) 
Hand 0.470 (0.180) .010   
Mean Force 
Fixed Effect Estimates  p Random Effect Variances  
Level 1 Variables   Level 1 residual (εit) 20.600 (4.538) 
Intercept 38.850 (2.371) < .001 Level 2 intercept (µ0i) 154.700 (12.439) 
% MVC 54.478 (2.371) < .001 % MVC 299.8 (17.316) 
Hand 0.220 (0.494) .657   
Level 2 Variables     
Group 0.351 (0.976) .719   
Interaction Variables     
Group x Hand 3.480 (0.988)  < .001   
Note: MVC: maximum voluntary contraction; Fixed effect estimate values are given as Estimate 
(Standard Error) and random effect variances are given as Variance (Standard Deviation)  
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Table 5  
 
Correlational Analyses of CGG and Visuomotor Outcomes (Spearman ρ Values) 
 
  2-second (“Pulse”) 8-second (“Sustained”) 
Dominant Hand 
 MVC Level MVC Level 
Dependent Variable 15% 45% 85% 15% 45% 85% 
Rise phase accuracy -0.209 -0.144 -0.379 0.024 -0.046 -0.010 
Rate of force increase 0.032 -0.151 0.277 -0.151 0.277 0.033 
Rise phase duration  0.193 0.015 0.169 0.015 0.169 0.137 
Rise phase latency 0.525* 0.437* 0.345 0.437* 0.345 0.124 
Mean force - - - -0.107 -0.128 -0.155 
ApEn - - - -0.330 -0.529** -0.453* 
Force SD - - - 0.222 0.191 0.320 
Rate of force relaxation -0.255 -0.272 -0.068 -0.272 -0.068 0.122 
Non-Dominant Hand 
Dependent Variable 15% 45% 85% 15% 45% 85% 
Rise phase accuracy -0.209 -0.144 -0.379 0.286 0.266 -0.246 
Rate of force increase 0.110 0.045 0.039 0.045 0.039 -0.195 
Rise phase duration  0.221 0.417* 0.200 0.417* 0.200 0.374 
Rise phase latency 0.214 0.457* 0.296 0.457* 0.296 0.355 
Mean force - - - -0.085 -0.103 -0.067 
ApEn - - - -0.388 -0.449* -0.382 
Force SD - - - 0.348 0.183 0.081 
Rate of force relaxation 0.056 -0.102 -0.008 -0.102 -0.008 -0.174 
Note: MVC: maximum voluntary contraction; CGG: cytosine-guanine-guanine; *p < .05; **p < .01; 
Rates of force relaxation are negative values, and so positive correlations indicate that an increase in CGG 
repeat length is associated with slower (i.e., less negative) rates of force relaxation.  
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Table 6  
 
Correlational Analyses of Total ICARS Scores and Visuomotor Outcomes (Spearman ρ Values) 
 
  2-second (“Pulse”) 8-second (“Sustained”) 
Dominant Hand 
 MVC Level MVC Level 
Dependent Variable 15% 45% 85% 15% 45% 85% 
Rise phase accuracy -0.343 0.081 -0.057 -0.112 0.121 -0.423 
Rate of force increase 0.519 0.459 0.470 -0.182 -0.117 0.053 
Rise phase duration  -0.353 -0.421 -0.124 -0.270 -0.022 0.068 
Rise phase latency 0.774** 0.703* 0.724** 0.612** 0.182 0.336 
Mean force - - - 0.139 0.083 0.085 
ApEn - - - -0.178 0.022 -0.195 
Force SD - - - 0.223 0.401 0.414 
Rate of force relaxation -0.827** -0.841** -0.636* -0.273 -0.163 -0.095 
Non-Dominant Hand 
Dependent Variable 15% 45% 85% 15% 45% 85% 
Rise phase accuracy -0.343 0.081 -0.057 -0.035 0.216 -0.427 
Rate of force increase 0.194 0.336 0.208 -0.305 0.012 -0.227 
Rise phase duration  -0.371 -0.389 -0.424 -0.018 0.200 0.005 
Rise phase latency 0.551 0.625* 0.795** 0.372 0.441 0.248 
Mean force - - - 0.092 0.143 0.113 
ApEn - - - -0.395 -0.173 -0.377 
Force SD - - - 0.339 0.663** 0.578* 
Rate of force relaxation -0.463 -0.399 -0.219 0.121 -0.014 0.383 
Note: MVC: maximum voluntary contraction; CGG: cytosine-guanine-guanine; *p < .05; **p < .01; 
Rates of force relaxation are negative values, and so positive correlations indicate that an increase in CGG 
repeat length is associated with slower (i.e., less negative) rates of force relaxation.
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Figure 1: The custom-made arm brace and load cells for laboratory testing. Participants pressed with their 
thumb and forefinger against two precision load cells while viewing two horizontal bars displayed 




Figure 2: Visuomotor test stimuli. Participants pressed when the red bar turned green in order to bring the 
white bar up to the target green bar. They were instructed to maintain their force level at the level of the 
green bar as steadily as possible.  
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Figure 3: Rise phase reaction time as a function of group, task, and age (linear fit with 95% confidence 
intervals). Relative to controls, premutation carriers demonstrate longer reaction times during the pulse 
task at younger ages. At older ages, premutation carriers show similar reaction times to controls during 
the pulse task. During the sustained task, premutation carriers, regardless of age, show similar reaction 
times, whereas older controls perform more slowly with age.  
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Figure 4: Peak rate of force increase (controlled for individual MVC) as a function of group, task, and % 
MVC. Relative to controls, premutation carriers show a reduced rate of force increase during the 85% 
MVC pulse task. Lower and upper box bounds represent the 25th and 75th percentiles, respectively. Upper 
and lower whiskers extend at most to 1.5 times the interquartile range.  
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Figure 5: Rise phase accuracy as a function of group, hand, and % MVC. A value of 1 reflects perfect 
accuracy. Relative to controls, premutation carriers overshoot target force levels when using their non-
dominant hand in low force conditions (15% and 45%). Lower and upper box bounds represent the 25th 




Figure 6: Approximate entropy (ApEn; i.e., force complexity) as a function of group, hand, and age 
(linear fit with 95% confidence intervals). During the dominant hand condition, younger premutation 
carriers demonstrated reduced force complexity, while premutation carriers across a broad age range 




Figure 7: A. CGG (cytosine-guanine-guanine) repeat length is associated with reduced non-dominant 
hand approximate entropy (ApEn), a measure of the complexity of force output, during the 45% MVC 
condition. B. Increased total ICARS scores (clinical severity) are associated with longer reaction time 
across multiple conditions (non-dominant, 85% MVC, pulse task is shown as a representative 
relationship). C. Increased total ICARS scores (clinical severity) are associated with increased force 
variability (force SD) during the non-dominant hand 45% MVC condition. D. Increased total ICARS 
scores (clinical severity) are associated with more negative (i.e., quicker) rates of force relaxation during 
multiple conditions (dominant, 15% MVC, pulse task is shown as a representative relationship). All 
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